Global Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Anti-Cathepsin B Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 is expected to have a positive impact on the anti-cathepsin B market owing to research and development of anti-cathepsin B antibodies to cure the COVID-19 infection. For instance, a report published by the Shanghai Pasteur Institute of Chinese Academy of Sciences in February 2020 showed that when a SARS-CoV-2 (virus) enters a cell through ACE2 and undergoes endocytosis, cathepsin then degrades the spike protein (S protein) to release the nucleic acids of the virus. Some evidence shows that cathepsin B/L inhibitor can block this process. The growth of the anti-cathepsin market as a result of the COVID-19 pandemic has created lucrative opportunities for growth of the anti-cathepsin B market.

Furthermore, the increasing research and development of a wide range of products, and mergers and acquisitions among key players are the major factors that are expected to drive growth of the anti-cathepsin B market during the forecast period.

The increasing research and development of anti-cathepsin B by different research institutes is expected to contribute significantly to the anti-cathepsin B market growth. For instance, according to data published by the National Center for Biotechnology Information (NCBI) in January 2016, variety of cathepsin B inhibitors have been developed and investigated for the inhibition of tumor invasion to treat different cancers, however none have succeeded in demonstrating clinical evidence to treat cancers. However, what has been learned from the use of inhibitors to block cathepsin B function is still valuable and will provide insights in the development of clinically useful agents.

As cathepsin B has been confirmed to play a vital role in invasion and metastasis, specific cathepsin B inhibitors will be more valuable for late stage cancers. In an immunocompetent model of breast cancer with spontaneous bone metastasis, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074, but not the broad spectrum cysteine cathepsin inhibitor JPM-OEt, reduced metastasis in tumor-bearing animals.

Browse 43 Market Data Tables and 39 Figures spread through 177 Pages and in-depth TOC on Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), by Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), by End User (Pharmaceutical Companies, and Academic and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to Anti-Cathepsin B market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anti-cathepsin-b-market-4169

Several market players are focused on inorganic strategies such as mergers and acquisitions to expand their product portfolio and gain maximum share in the market. For instance, in November 2015, Germany's Merck KGaA announced the completion of its US$ 17 billion acquisition of Sigma-Aldrich, following approval from the European Commission. Following the acquisition, Merck will have an offering of 300,000 products with highly-respected brands and products including cathepsin Inhibitors, around 50,000 employees in 67 countries, and working at 72 manufacturing sites worldwide. Along with Sigma-Aldrich, Merck has created strategic marketing and innovation teams (SMIs) to promote and deliver innovation tailored to its life science customers’ needs. Furthermore, Sigma-Aldrich and Merck will be able to serve life science customers around the world with a highly attractive set of established brands such as SAFC and BioReliance, in addition to Millipore and Milli-Q.

Key Takeaways of the Anti-Cathepsin B Market:

  • The anti-cathepsin B market is expected to exhibit a CAGR of 2.8% during the forecast period (2020-2027) owing to the increasing research and development activities and clinical trials.
  • Major players offering a wide range of products which is expected to boost growth of the anti-cathepsin B market during the forecast period. For example, Santa Cruz Biotechnology offers a broad range of cathepsin B Inhibitors and Cathepsin inhibitor peptides, E-64-d, E-64, Chymostatin, CA-074 methyl ester, Calpain Inhibitor VI, Mu-Phe-hPhe-FMK, E-64-c, CA-074, Cathepsin B inhibitor, Leupeptin trifluoroacetate salt, Caspase Inhibitor Negative Control, and Biotin-FA-FMK. Cathepsin B inhibitor is a cell-permeable, irreversible cathepsin B inhibitor that may be potentially useful in treating arthritis. Cathepsin B has been found to be involved in demyelination, emphysema, rheumatoid arthritis, and neoplastic infiltration.
  • Major players operating in the anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner